查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963954

個人化醫療生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、疾病、地區和競爭格局分類，2021-2031年

Personalized Medicine Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Indication, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球個人化醫療生物標記市場預計將從 2025 年的 159.9 億美元成長到 2031 年的 233.4 億美元，複合年成長率為 6.51%。

這些生物標記，包括基因、蛋白質和基因突變等特定生物分子，對於識別特定治療性介入的最佳患者亞群以及預測不良反應至關重要。該市場的成長主要得益於基因測序技術的快速發展以及醫療保健模式向標靶治療的模式轉移，後者旨在最大限度地提高療效並最大限度地降低毒性。癌症等慢性疾病的日益普遍以及伴隨診斷在藥物研發中的應用不斷擴大，進一步加速了這一轉變。根據個人化醫療聯盟（Personalized Medicine Coalition）統計，美國食品藥物管理局（FDA）在2024年核准了18種新的個人化藥物，約佔新核准治療性分子實體的38%，凸顯了該領域在現代醫學中日益成長的影響力。

市場概覽
預測期 2027-2031
市場規模：2025年 159.9億美元
市場規模：2031年 233.4億美元
複合年成長率：2026-2031年 6.51%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

儘管生物標記檢測具有巨大的成長潛力，但其複雜的報銷環境為市場帶來了重大障礙。支付者往往難以評估生物標記檢測的價值，導致保險覆蓋政策不一致，限制了患者獲得這些關鍵診斷工具的機會。此外，開發和檢驗新型生物標記的高昂成本也對小規模的生物技術公司構成了巨大的財務障礙。因此，儘管科學創新不斷加速，但監管核准和報銷機制之間的不一致仍然是一個重大挑戰，有可能減緩個人化醫療解決方案在全球範圍內的商業性化應用。

市場促進因素

次世代定序和基因組學技術的快速發展正在推動市場成長，實現了基因突變和表現模式的高通量識別。這些技術進步使研究人員能夠分析大量的遺傳資訊資料集，加速發現對精準醫療發展至關重要的新型生物標記。利用強大的定序基礎設施進行疾病感受性作圖和治療標靶識別的領先舉措，展現了大規模處理基因組數據的能力。根據英國生物銀行於2023年11月發布的全球最大規模的基因資料發布，來自50萬名參與者的全基因測序資料已向核准研究人員開放。這是進行遺傳標記與健康結果之間相關性分析的重要資源，有助於縮短將研究成果轉化為臨床工具的時間。

同時，全球癌症和慢性病發病率的上升對市場產生了重大影響，使得標靶治療的引入對於提高患者存活率至關重要。面對日益沉重的複雜疾病負擔，醫療系統正擴大利用生物標記對患者進行分層，並選擇合適的治療性介入。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告，預計僅2024年美國就將新增2,001,140例癌症病例，凸顯了精準診斷技術的緊迫性。疾病發生率的上升迫使製藥公司優先考慮以生物標記主導的藥物研發。例如，阿斯特捷利康於2024年2月發布的《2023會計年度年度報告及20-F表格資訊》指出，其臨床開發平臺中約90%為標靶治療，這反映了整個產業向個人化醫療的轉變。

市場挑戰

複雜的診斷檢測報銷機制嚴重阻礙因素了全球個人化醫療生物標記市場的發展。支付者和保險公司常常難以對這些先進的診斷技術應用統一的價值評估框架，導致保險覆蓋範圍難以預測，拒保率居高不下。這種不確定性給醫療服務提供者帶來了挑戰，可能導致他們因行政障礙和潛在的經濟責任而猶豫是否進行必要的生物標記檢測。因此，新型生物標記的商業性可行性受到損害，相關標靶治療的推出也被顯著延緩。

保險覆蓋範圍的不匹配直接阻礙了市場滲透，影響了診斷的可及性和患者的就醫途徑。缺乏可靠的報銷機制，個人化醫療的普及程度仍不盡人意，限制了研發者的商機。根據個人化醫療聯盟（Personalized Medicine Coalition）預測，到2024年，僅有36%的進行性非小細胞肺癌患者（他們可能受益於個人化醫療）能夠獲得治療，這凸顯了這些就醫障礙的嚴重影響。這些數據表明，儘管科學取得了突破性進展，但報銷模式未能跟上臨床創新步伐，嚴重阻礙了市場成長。

市場趨勢

液態生物檢體的日益普及正推動市場從靜態組織取樣轉向動態、非侵入性監測。這項技術能夠檢測循環腫瘤DNA並即時識別抗藥性機制，使臨床醫生能夠在避免重複切片檢查風險的前提下調整治療方案。隨著治療方案選擇和復發追蹤中對血液檢測的依賴性不斷增強，液體活體組織切片的商業性發展勢頭也日益強勁。根據Guardant Health於2024年5月發布的2024年第一季財報，臨床檢測量年增20%至46,900例，顯示精準醫療管理中對液態生物檢體的依賴性日益增強。

同時，人工智慧的引入正在革新整合多模態資料集的生物標記發現方法。計算工具分析基因組數據和臨床數據之間的相互作用，識別出傳統方法忽略的預測性特徵，從而提高臨床試驗的成功率。這種數據驅動方法建構的龐大資料庫為演算法診斷和個人化醫療策略提供了支援。 Tempus AI在2024年5月向美國證券交易委員會提交的S-1表格註冊聲明中披露，其多模態資料庫的資料量已超過Petabyte，這充分展現了支撐生物標記開發的數位基礎設施的龐大規模。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：個人化醫療生物標記的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按應用領域（早期檢測/篩檢、適應症、治療選擇、監測）
    • 疾病特定類別（腫瘤科、神經科、糖尿病科、自體免疫疾病科、心臟科、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美個人化醫療生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲個人化醫療生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區個人化醫療生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲個人化醫療生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲個人化醫療生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球個人化醫療生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.
  • Genome Medical, Inc.
  • Coriell Life Sciences.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23939

The Global Personalized Medicine Biomarkers Market is projected to expand from USD 15.99 Billion in 2025 to USD 23.34 Billion by 2031, reflecting a CAGR of 6.51%. These biomarkers, which include specific biological molecules like genes, proteins, or genetic variations, are essential for identifying patient subgroups best suited for particular therapeutic interventions or for predicting adverse reactions. The market is primarily driven by rapid breakthroughs in genomic sequencing technologies and a healthcare paradigm shift toward targeted therapies that maximize treatment efficacy while minimizing toxicity. This transition is further reinforced by the rising prevalence of chronic conditions such as cancer and the increasing incorporation of companion diagnostics into drug development. According to the Personalized Medicine Coalition, the U.S. FDA approved 18 new personalized medicines in 2024, accounting for approximately 38 percent of all newly authorized therapeutic molecular entities, highlighting the sector's growing impact on modern medicine.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 15.99 Billion
Market Size 2031USD 23.34 Billion
CAGR 2026-20316.51%
Fastest Growing SegmentOncology
Largest MarketNorth America

Despite this strong growth potential, the market faces significant hurdles due to the complicated reimbursement landscape for diagnostic tests. Payers often find it difficult to assess the value of biomarker testing, resulting in inconsistent coverage policies that restrict patient access to these critical diagnostic tools. Additionally, the substantial costs involved in developing and validating novel biomarkers present a high financial barrier for smaller biotechnology firms. Consequently, while scientific innovation continues to accelerate, the misalignment between regulatory approval and reimbursement mechanisms remains a critical challenge that threatens to slow the widespread commercial adoption of personalized medicine solutions globally.

Market Driver

Rapid advancements in next-generation sequencing and genomic technologies act as a primary catalyst for the market, enabling high-throughput identification of genetic mutations and expression patterns. These technical improvements allow researchers to analyze immense datasets of genetic information, facilitating the discovery of novel biomarkers crucial for developing precision therapies. The capacity to process genomic data at scale is demonstrated by major initiatives that utilize robust sequencing infrastructure to map disease susceptibility and pinpoint therapeutic targets. According to the UK Biobank, in its November 2023 announcement regarding the release of the world's largest genetic dataset, whole genome sequencing data from 500,000 participants was made available to approved researchers, providing a vital resource for correlating genetic markers with health outcomes and shortening the timeline for translating insights into clinical tools.

Simultaneously, the market is heavily influenced by the rising global prevalence of cancer and chronic diseases, which necessitates the adoption of targeted treatment regimens to enhance patient survival rates. As the burden of complex pathologies increases, healthcare systems increasingly rely on biomarkers to stratify patients and select appropriate therapeutic interventions. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024, it is projected that there will be 2,001,140 new cancer cases in the United States alone in 2024, underscoring the urgent need for precise diagnostic modalities. This growing disease incidence compels pharmaceutical companies to prioritize biomarker-driven drug development; for instance, AstraZeneca's 'Annual Report and Form 20-F Information 2023' from February 2024 noted that approximately 90 percent of its clinical pipeline consisted of targeted therapies, reflecting an industry-wide commitment to personalized medicine.

Market Challenge

The intricate reimbursement landscape for diagnostic tests operates as a severe constraint on the growth of the Global Personalized Medicine Biomarkers Market. Payers and insurers frequently struggle to apply consistent value assessment frameworks to these advanced diagnostics, leading to unpredictable coverage decisions and high denial rates. This uncertainty creates a difficult environment for healthcare providers, who may hesitate to order essential biomarker tests due to administrative hurdles and potential financial liabilities. As a result, the commercial viability of novel biomarkers is compromised, and the uptake of associated targeted therapies is significantly delayed.

This misalignment in coverage directly impedes market penetration by disconnecting diagnostic availability from patient access. Without reliable reimbursement pathways, the adoption of personalized medicine remains suboptimal, limiting revenue opportunities for developers. According to the Personalized Medicine Coalition, in 2024, personalized medicines reached only 36 percent of potentially eligible advanced non-small cell lung cancer patients, highlighting the profound impact of these access barriers. Such data illustrates that despite scientific breakthroughs, the market's trajectory is heavily suppressed by the inability of reimbursement models to keep pace with clinical innovation.

Market Trends

The widespread adoption of liquid biopsy is transitioning the market from static tissue sampling to dynamic, non-invasive monitoring. This technology detects circulating tumor DNA to identify resistance mechanisms in real time, enabling clinicians to adjust treatments without the risks associated with repeat biopsies. Commercial momentum is accelerating as providers increasingly rely on blood-based testing for therapy selection and recurrence tracking. According to Guardant Health's 'First Quarter 2024 Financial Results' press release in May 2024, the company reported a 20 percent year-over-year increase in clinical test volume to 46,900 tests, illustrating the growing dependence on liquid biopsy for precision management.

At the same time, the implementation of artificial intelligence is reshaping biomarker discovery by integrating multi-modal datasets. Computational tools analyze interactions between genomic and clinical data to identify predictive signatures that traditional methods overlook, thereby increasing the success rates of clinical trials. This data-driven approach creates extensive libraries that fuel algorithmic diagnostics and personalized care strategies. According to Tempus AI, in its 'Form S-1 Registration Statement' filed with the U.S. Securities and Exchange Commission in May 2024, the organization disclosed that its multimodal database grew to include over 200 petabytes of data, demonstrating the massive scale of digital infrastructure now supporting biomarker development.

Key Market Players

  • Laboratory Corporation of America Holding
  • Quest Diagnostics Incorporated
  • Agilent Technologies, Inc.
  • Genome Medical, Inc.
  • Coriell Life Sciences.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.

Report Scope

In this report, the Global Personalized Medicine Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Personalized Medicine Biomarkers Market, By Application

  • Early Detection/Screening
  • Indication
  • Treatment Selection
  • Monitoring

Personalized Medicine Biomarkers Market, By Indication

  • Oncology
  • Neurology
  • Diabetes
  • Autoimmune Diseases
  • Cardiology
  • Others

Personalized Medicine Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Personalized Medicine Biomarkers Market.

Available Customizations:

Global Personalized Medicine Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Personalized Medicine Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Early Detection/Screening, Indication, Treatment Selection, Monitoring)
    • 5.2.2. By Indication (Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Personalized Medicine Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Indication
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Personalized Medicine Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Indication
    • 6.3.2. Canada Personalized Medicine Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Indication
    • 6.3.3. Mexico Personalized Medicine Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Indication

7. Europe Personalized Medicine Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Indication
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Personalized Medicine Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Indication
    • 7.3.2. France Personalized Medicine Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Indication
    • 7.3.3. United Kingdom Personalized Medicine Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Indication
    • 7.3.4. Italy Personalized Medicine Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Indication
    • 7.3.5. Spain Personalized Medicine Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Indication

8. Asia Pacific Personalized Medicine Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Indication
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Personalized Medicine Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Indication
    • 8.3.2. India Personalized Medicine Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Indication
    • 8.3.3. Japan Personalized Medicine Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Indication
    • 8.3.4. South Korea Personalized Medicine Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Indication
    • 8.3.5. Australia Personalized Medicine Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Indication

9. Middle East & Africa Personalized Medicine Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Indication
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Personalized Medicine Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Indication
    • 9.3.2. UAE Personalized Medicine Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Indication
    • 9.3.3. South Africa Personalized Medicine Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Indication

10. South America Personalized Medicine Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Indication
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Personalized Medicine Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Indication
    • 10.3.2. Colombia Personalized Medicine Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Indication
    • 10.3.3. Argentina Personalized Medicine Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Personalized Medicine Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Laboratory Corporation of America Holding
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quest Diagnostics Incorporated
  • 15.3. Agilent Technologies, Inc.
  • 15.4. Genome Medical, Inc.
  • 15.5. Coriell Life Sciences.
  • 15.6. Thermo Fisher Scientific Inc.
  • 15.7. NeoGenomics Laboratories, Inc.
  • 15.8. FOUNDATION MEDICINE, INC.
  • 15.9. Illumina, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer